Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1658-1660

  Brow, Ross ^a   Suen, Hayley ^a   Favaloro, James ^a   Yang, Shihong ^a   Ho, P Joy ^a   Gibson, John ^a   Joshua, Douglas ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Dendritic cell; Immunosurveillance; Immunotherapy; Multiple myeloma; T cell; T cell clones; Th17; Treg; Trogocytosis

Indexed keywords

CD28 ANTIGEN; CD45RA ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; COMPLEMENT COMPONENT C3D; HLA G ANTIGEN; PERFORIN; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN EXPRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; DENDRITIC CELL; ENDOCYTOSIS; HUMAN; IMMUNE DYSREGULATION; IMMUNOSURVEILLANCE; MULTIPLE MYELOMA; NATURAL KILLER T CELL; NOTE; PLASMA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; TH17 CELL; TROGOCYTOSIS; UPREGULATION;

EID: 84885335303     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22032     Document Type: Note

References (10)

1. Brown R, Kabani K, Favaloro J, Yang S, Ho PJ, Gibson J, et al. CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis. Blood 2012; 120:2055-63.
2. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117:1167-74
3. Li J, Sze DM, Brown RD, Cowley MJ, Kaplan W, Mo SL, et al. Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy. Blood 2010; 115:3580-8
4. Raitakari M, Brown RD, Sze D, Yuen E, Barrow L, Nelson M, et al. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br J Haematol 2000; 110:203-9
5. Brown RD, Spencer A, Ho PJ, Kennedy N, Kabani K, Yang S, et al. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leuk Lymphoma 2009; 50:1860-4
6. Sze DM-Y, Giesajtis G, Brown RD, Raitakari M, Gibson J, Ho J, et al. Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8(+) CD57(+)CD28(-) compartment. Blood 2001; 98:2817-27
7. Brown RD, Pope B, Murray A, Esdale W, Hart D, Gibson J, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001; 98:2992-8
8. Brown R, Murray A, Pope B, Sze DM, Gibson J, Ho PJ, et al. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br J Haematol 2004; 125:743-8
9. Joshua DE, Brown RD, Ho PJ, Gibson J. Regulatory T cells and multiple myeloma. Clin Lymphoma Myeloma 2008; 8:283-6
10. LeMaoult J, Caumartin J, Daouya M, Favier B, Le Rond S, Gonzalez A, et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 2007; 109:2040-8